In this issue of Cancer Cell, Fröhling and colleagues tackle this challenge admirably for the known cancer gene FLT3 in acute myeloid leukemia—undertaking a systematic resequencing and functional validation approach, identifying important rare driver mutations as well as passenger mutations in patients negative for the more common activating mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.